AI-generated analysis. Always verify with the original filing.
Sensei Biotherapeutics reported a 2025 net loss of $21.1M with $21.2M cash, completing the Faeth acquisition and a $200M private placement to fund PIKTOR's Phase 2 endometrial and Phase 1b breast cancer trials through year-end 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
and the exhibit attached hereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as ame
| Financial Statements and Exhibits. | |---|---| (d) Exhibits Exhibit Number: 99.1 | Exhibit Description: Press Release of Sensei Biotherapeutics, Inc., dated M
| Metric | Value | Basis |
|---|---|---|
| Net Loss | $-21.1K | GAAP |
| Net Loss Per Share | $-16.72 | GAAP |
| Research and Development Expenses | $11.0K | GAAP |
| General and Administrative Expenses | $11.3K | GAAP |
| Loss From Operations | $-22.3K | GAAP |
| Weighted-Average Common Shares Outstanding | $1.3M |
Acquisition / Disposition